Synergistic Effect of Non-Transmissible Sendai Virus Vector Encoding c-myc Suppressor FUSE-Binding Protein-Interacting Repressor Plus Cisplatin in Malignant Pleural Mesothelioma Treatment

Strategic Insights -

A recent study published in Cancer Science has revealed promising therapeutic potential for the treatment of malignant pleural mesothelioma (HMPM) using a combination of a non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor (FIR) and cisplatin. The study, conducted by researchers from Chiba University in Japan, demonstrated that the combination therapy showed significant tumor reduction and improvement in survival rate in an animal model. This novel approach has the potential to provide an attractive modality against HMPM.

Key Takeaways:

  • The study reported that HMPM is highly resistant to conventional therapy, highlighting the need for novel therapies.
  • The non-transmissible Sendai virus vector encoding FIR (SeV/?F/FIR) was prepared and showed significant cytotoxic activity against HMPM cells in combination with cisplatin.
  • SeV/?F/FIR reduced cell viability in three HMPM cell lines, while being less effective in non-tumor immortalized mesothelial cells.
  • The cytotoxicity of SeV/?F/FIR was partly due to apoptosis induction via c-Myc suppression.
  • Combination therapy with SeV/?F/FIR plus cisplatin showed synergistic antitumor effects, as revealed by isobologram analysis in MSTO-211H.
  • The study concluded that SeV/?F/FIR plus cisplatin has therapeutic potential against HMPM and will be an attractive modality in the future.
  • The researchers emphasized the need for further investigation into the safety and efficacy of this novel combination therapy.

Statistics:

  • 3 HMPM cell lines showed reduced cell viability in response to SeV/?F/FIR in combination with cisplatin.
  • 1 HMPM cell line, MSTO-211H, showed synergistic antitumor effects with SeV/?F/FIR plus cisplatin.
  • The study reported significant tumor reduction and improvement in survival rate in an animal model treated with SeV/?F/FIR plus cisplatin.
  • The therapeutic potential of SeV/?F/FIR plus cisplatin against HMPM was demonstrated in a combination of in vitro and in vivo studies.

Sources:

  • Kitamura A., et al. (2011) Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Science, 102(7), 1366-1373.
  • Gene Therapy Weekly editors (2011) New Study Finds Promising Therapeutic Potential for Malignant Pleural Mesothelioma Treatment. Gene Therapy Weekly via NewsRx.com.